Lexicon Pharmaceuticals, Inc
Lexicon Pharmaceuticals is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines. Its business today centers on INPEFA (sotagliflozin), an approved cardiovascular drug in the U.S., while it also advances pipeline programs such as sotagliflozin for hypertrophic cardiomyopathy and pilavapadin for neuropathic pain.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueINPEFA sales in the United States for approved cardiovascular indications.
Pipeline programs including sotagliflozin and pilavapadin under clinical development.
Upfront, milestone, and other revenue from strategic partnerships such as Novo Nordisk.
Products
Reported · share of revenue- License90.6 %
- Products9.4 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Lexicon sells primarily to patients through the healthcare system, with prescribing decisions driven by physicians and reimbursement decisions by payers. Its commercial product is used in cardiovascular care, while its pipeline targets specialist-treated conditions such as hypertrophic cardiomyopathy, type 1 diabetes, and neuropathic pain. The company also relies on collaborators and licensees as a meaningful source of revenue.
Cardiologists and other clinicians prescribe INPEFA and evaluate pipeline drugs based on efficacy, safety, and convenience.
Patients with cardiovascular or specialty disease conditions use the approved product or may enroll in clinical programs.
Commercial insurers and government programs influence uptake through coverage and reimbursement decisions.
Partners such as Novo Nordisk provide licensing revenue and may help fund or advance development assets.
Strategy
Lexicon is prioritizing commercialization of INPEFA while continuing to invest heavily in its clinical pipeline. It is also pursuing value creation through late-stage development of sotagliflozin in HCM, regulatory efforts for ZYNQUISTA, and partnership-based monetization through collaborations and licenses. Supply-chain resilience and backup sourcing are part of the operating strategy to support both commercial supply and clinical development.
The approved product is the main near-term source of product revenue and market presence.
Positive Phase 3 data could expand the addressable market and extend the sotagliflozin franchise.
A successful resubmission or hearing outcome could reopen a diabetes opportunity.
Commercial supply depends on third-party manufacturers and logistics providers, so redundancy reduces disruption risk.
Geography
Lexicon is operationally centered in the United States, where it commercializes INPEFA and manages most corporate activity. Its supply chain is international, with raw materials sourced from Asia and Europe and API/finished-product manufacturing and storage spread across North America and Asia. The company also notes that substantially all sales to date have been in U.S. dollars, indicating limited current foreign revenue exposure.
Risks
Lexicon faces the classic biotech risk profile: clinical trials may fail, regulators may not approve new indications, and commercial uptake may lag if payers or physicians do not adopt the product. The company also depends on a concentrated third-party manufacturing and logistics network, which creates supply interruption risk, while its limited revenue base and history of losses increase financing pressure.
- Clinical development failureImpact: HighLikelihood: High
Pipeline value depends on positive trial outcomes, and late-stage trials can fail even after earlier promise.
Exposure: SONATA-HCM and other drug candidates
- Regulatory delay or denialImpact: HighLikelihood: High
FDA review of new indications and resubmissions is uncertain and can materially delay commercialization.
Exposure: ZYNQUISTA and future label expansions
- Capital and dilution riskImpact: HighLikelihood: High
Persistent losses and ongoing R&D spending may require external funding before profitability.
Exposure: Corporate financing and shareholder dilution
- Third-party manufacturing concentrationImpact: HighLikelihood: Medium
The company relies on sole or single-source suppliers for key API, drug product, and logistics functions.
Exposure: Commercial INPEFA supply chain
- Reimbursement and market acceptanceImpact: MediumLikelihood: Medium
Sales depend on coverage decisions and physician confidence in comparative benefit and safety.
Exposure: INPEFA commercial uptake
Accounting
Judgemental itemsUpfront and milestone payments from alliances can be recognized at different times, affecting comparability across quarters.
Impact: Novo Nordisk licensing revenue materially affected 2025 revenue
Commercial and clinical inventory is held across third-party locations, requiring reserve judgments for shelf life and demand.
Impact: Can affect cost of sales and gross margin
Employee and consultant equity awards are a recurring non-cash expense in a development-stage biotech.
Impact: Impacts operating loss and diluted share count
Clinical trial accruals, external research costs, and manufacturing commitments require estimates and true-ups.
Impact: Affects operating expenses and period comparability
Similar listed companies
Publicly listed companies with a comparable business focus.
Reviva Pharmaceuticals Holdings, Inc.
RVPH · Pharmaceutical Preparations
Scilex Holding Co
SCLXW · Biological Products, (No Diagnostic Substances)
Scilex Holding Co is a U.S.-based biopharmaceutical company focused on non-opioid pain management and other specialty pharmaceutical products.
Inventiva S.A.
IVA · Pharmaceutical Preparations
Prothena Corporation plc
PRTA · Pharmaceutical Preparations
Prothena Corp.
Windtree Therapeutics Inc /De/
WINT · Biological Products, (No Diagnostic Substances)
Windtree Therapeutics is a U.S.-based biotechnology company focused on developing therapies for cardiovascular disease, hypertension, and oncology.
Sonoma Pharmaceuticals, Inc.
SNOA · Surgical & Medical Instruments & Apparatus
Sonoma Pharmaceuticals develops and sells stabilized hypochlorous acid (HOCl) products used in wound care, eye care, oral care, dermatology, podiatry, animal health care, and surface disinfection.
Last updated: 24/09/2026